Previous 10 | Next 10 |
PrimiSleep™ Enters Rapidly Growing Global Sleep Aid Market With State-of-the-Art Supplement LAS VEGAS, NV, July 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT ), is pleased to announce the launch of a new, anti-stress, all...
Responding to Consumers, Management Offers Cost-Effective Combination With Enhanced Synergistic Benefits LAS VEGAS, NV , June 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT ), responding to heightened interest and demand largely generate...
Las Vegas, NV - ( NewMediaWire ) - June 23, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT), has launched its advanced proprietary supplement for dogs, Canine All-in-One , a daily dose formulation, patterned after its highly successful product for horses, Equine All-In-One . Can...
Management Pursues Growth By Bringing Advanced Wellness Through Advantageous Senior Pricing Las Vegas, NV - ( NewMediaWire ) - June 09, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT ). In response to urgent and growing inflationary concerns expressed by the latest generation...
Las Vegas, NV - ( NewMediaWire ) - June 02, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D. Dr. Sutton, who previously summarized her successful use of PluriPain ...
Las Vegas, NV - ( NewMediaWire ) - February 25, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT), In reference to the previous Press Release of February 24, 2022, the Company announced today that it will continue providing Pluripain® and monitoring the use of this product by those suffer...
Las Vegas, NV - ( NewMediaWire ) - February 24, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT) announced today positive results from a study conducted by Stanford Medical School Professor, Lorrin Koran, M.D., regarding the use of Pluripain® to manage the symptoms of Gadolinium Depositi...
LAS VEGAS, NV, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today positive results from a study conducted by Stanford Medical School Professor, Lorrin Koran, M.D., regarding the use of Pluripain® to manage the sympto...
Company closes on Patented Technology acquisition; plans new products through wholly-owned subsidiary Las Vegas, NV - ( NewMediaWire ) - February 03, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it has entered into a definitive agreement with inventor Thomas J. Mohr...
Company to study OSCPeP device usage for active smokers and second-hand exposure Las Vegas, NV - ( NewMediaWire ) - January 27, 2022 - BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it is commencing preliminary investigation into the clinical utilization of its Lung Armor&...
News, Short Squeeze, Breakout and More Instantly...
LAS VEGAS, NV, April 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today the intention to spin off its Livestock Impact Division as a wholly-owned subsidiary. The new company will continue to develop and market natural suppleme...
Las Vegas, NV - ( NewMediaWire ) - April 18, 2023 - BioAdaptives, Inc. (OTCMkts: BDPT) announced today the signing of a non-exclusive license agreement with LY Research Corporation to market a patented resveratrol product (patent US # 6,855,353) for animals and humans. Edward Jacobs, M...
Las Vegas, NV - ( NewMediaWire ) - April 13, 2023 - BioAdaptives, Inc. (OTCMkts: BDPT) announced today the appointment of David Allen, PhD to its Board of Directors. Edward Jacobs, M.D., CEO BioAdaptives, Inc., comments, “We are very pleased to be joined by David Allen, PhD on our Boa...